SCHEDULE 13G/A: Capital Research Global Investors Discloses 7.0% Stake in iRhythm Technologies

Capital Research Global Investors has filed an amended Schedule 13G, reporting a beneficial ownership of 7.0% in iRhythm Technologies, Inc.'s common stock as of March 31, 2025.

Summary

• Capital Research Global Investors (CRGI) has filed an Amendment No. 3 to Schedule 13G regarding its beneficial ownership in iRhythm Technologies, Inc.
• As of March 31, 2025, CRGI beneficially owns 2,202,622 shares of iRhythm Technologies' Common Stock.
• This ownership represents 7.0% of the total class of securities, based on 31,409,617 shares believed to be outstanding.
• CRGI, a division of Capital Research and Management Company, holds sole voting power and sole dispositive power over all 2,202,622 shares.
• The filing indicates that the securities were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing control of the issuer.

Sentiment

Score: 5

Explanation: The document is a factual disclosure of beneficial ownership and does not contain information that would inherently indicate a positive or negative sentiment regarding the company's performance or future prospects. It simply reports an institutional investor's stake.

Positives

• The filing indicates continued significant investment by a major institutional investor, Capital Research Global Investors, holding a 7.0% stake.
• The investment is stated to be in the ordinary course of business, suggesting a long-term investment perspective rather than an activist stance.

Future Outlook

NA

Industry Context

This filing reflects an institutional investor's continued or updated position in a medical technology company specializing in cardiac monitoring. Such filings are routine disclosures of significant ownership stakes and do not typically provide insights into broader industry trends beyond confirming investor interest in the sector.

Stakeholder Impact

• Shareholders: The disclosure of a significant stake by a reputable institutional investor like Capital Research Global Investors may be viewed positively, potentially signaling confidence in the company's long-term value.

Key Dates

Keywords

iRhythm Technologies, Capital Research Global Investors, Schedule 13G, Beneficial Ownership, Common Stock, Medical Devices, Healthcare Technology, Institutional Investor, SEC Filing